Skip to content
10-K

Annual Report

Artiva Biotherapeutics, Inc. ARTV

0000950170-25-043837

← back to feed
Filed
Mar 24, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2024 · Mar 19, 2025 24.36M sh
Shares Diluted FY 2024 · Dec 31, 2023 802.75K sh
Capex FY 2024 · Dec 31, 2023 $3.26M
Operating Cash Flow FY 2024 · Dec 31, 2023 −$47.43M
Short Term Investments FY 2024 · Dec 31, 2023 $23.47M
Cash And Equivalents FY 2024 · Dec 31, 2023 $53.5M
Current Liabilities FY 2024 · Dec 31, 2023 $12.23M
Total Liabilities FY 2024 · Dec 31, 2023 $50.72M
Current Assets FY 2024 · Dec 31, 2023 $79.82M
Total Assets FY 2024 · Dec 31, 2023 $105.11M
Eps Diluted FY 2024 · Dec 31, 2023 −$35.78
Eps Basic FY 2024 · Dec 31, 2023 −$35.78
Sga Expense FY 2024 · Dec 31, 2023 $13.91M
Rd Expense FY 2024 · Dec 31, 2023 $50.25M
Net Income FY 2024 · Dec 31, 2023 −$28.72M
Operating Income FY 2024 · Dec 31, 2023 −$30.67M
Revenue FY 2024 · Dec 31, 2023 $32.92M
Stockholders Equity FY 2024 · Dec 31, 2022 −$140.7M